Consensus Amgen Inc. Sao Paulo

Stocks

AMGN34

BRAMGNBDR004

Pharmaceuticals

Market Closed - Sao Paulo 21:09:00 18/09/2026 BST			5-day change	1st Jan Change
75.00 ^BRL	-7.06%		+8.38%	+13.71%

09-16	Sling Therapeutics raises $123 million to advance thyroid eye disease drug	RE
09-15	Amgen Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM

02580c3fb176e09f9f5ff8.VcDIJLXpaMEfHVOgW_KL5lb52KKHmWCOO3Uxzv76210.PJmXHPKcJ_QvfDXIK5X_qjGsgvC-yye2Vw98nIejtwwUjvxL_6ZFrnNqZw~4722f7eb1899f8f768fabd9c8b744651

Analysts' recommendations: Amgen Inc.

09-10	HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445	MT
09-08	Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says	MT
09-08	Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating	MT
09-08	BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450	MT
09-08	Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy…
09-07	Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks…
09-04	Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating	MT
08-20	Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating	MT
08-19	Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating	MT
08-19	Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating	MT
08-18	Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating	MT
08-18	Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating	MT
08-17	Mizuho Securities Adjusts Amgen Price Target to $352 From $303	MT
08-13	Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating	MT
08-13	Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating	MT
08-10	HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating	MT
08-07	Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating	MT
08-06	Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating	MT
08-05	Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating	MT
08-05	UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating	MT
08-05	JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating	MT
08-05	Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating	MT
08-05	Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating	MT
08-05	TD Cowen Adjusts Price Target on Amgen to $452 From $420, Maintains Buy Rating	MT
08-05	Goldman Sachs Adjusts Price Target on Amgen to $450 From $427, Maintains Buy Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+14.96%
	JOHNSON & JOHNSON					+2.93%
	ABBVIE INC.					+5.55%
	ROCHE HOLDING AG					+5.2%
	NOVARTIS AG					+9.33%
	ASTRAZENECA PLC					+26.46%
	AMGEN INC.					+0.53%
	NOVO NORDISK A/S					+10.16%
	GILEAD SCIENCES, INC.					+5.35%
	Average					+8.94%
	Weighted average by Cap.					+9.46%